Skip to content

Lymphatic Mapping After Previous Breast Surgery

Lymphatic Mapping After Previous Breast Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01164748
Acronym
LABS
Enrollment
Unknown
Registered
2010-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2010-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Sentinel Node

Brief summary

Rationale: Like in primary breast cancer, prognosis in recurrent breast cancer is correlated with regional lymph node status. Therefore, axillary staging may be warranted in patients with recurrent disease and intact axillary nodes, although this has not been described in guidelines yet. The lymphatic drainage pathways in the breast and/or axilla could have been changed due to prior surgery and/or radiotherapy. These aberrant drainage pathways could be detected with lymphatic mapping and sentinel node biopsy (SNB), leading to a more accurate staging. Objective: To assess the technical feasibility of lymphoscintigraphy after prior breast surgery. A second goal is to investigate whether or not previous breast surgery (with or without radiotherapy) significantly changes the lymphatic drainage pathways of the breast.

Interventions

in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla

Sponsors

Catharina Ziekenhuis Eindhoven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* treatment with BCT with SNB and/or ALND for primary breast cancer * previous primary breast cancer located in the upper-outer quadrant of one breast * Primary breast cancer treatment at least 3 years before the analysis, with or without adjuvant chemo- or hormonal therapy.

Exclusion criteria

* breast surgery for other reasons than breast cancer * recurrent breast cancer * former allergic reaction to 99mTc-colloidal albumin.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026